ERASCA, INC.

(ERAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ERASCA, INC.
05/12Erasca Narrows Q1 Loss, Misses Street Estimates
MT
05/12Earnings Flash (ERAS) ERASCA Reports Q1 Loss $-0.31
MT
05/12Erasca Reports First Quarter 2022 Financial Results and Business Updates
GL
05/12Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/03Erasca to Present at the Bank of America Securities 2022 Healthcare Conference
AQ
04/27Erasca Appoints Jean Liu to its Board of Directors
AQ
04/27Erasca Appoints Jean Liu to its Board of Directors
CI
04/12Erasca Says Data Support Clinical Development of Certain Programs
MT
04/12Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentia..
AQ
04/06Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportun..
AQ
03/25NORTH AMERICAN MORNING BRIEFING : Dow Futures -2-
DJ
03/24ERASCA : Reports Fourth Quarter 2021 Financial Results and Business Updates - Form 8-K
PU
03/24Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
CI
03/24Erasca, Inc. Expects Initial Phase 1b Monotherapy Data in Second Half of 2022
CI
03/24Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates
AQ
03/24Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/18NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
03/10Erasca, Eli Lilly to Collaborate in Oncologic Clinical Trial
MT
03/10Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and C..
AQ
03/08Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting
AQ
02/03Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day
AQ
01/18Erasca Strengthens Leadership Team with Two Key Executive Appointments
GL
01/18Erasca Strengthens Leadership Team with Two Key Executive Appointments
GL
01/18Erasca, Inc. Announces Executive Changes
CI
01/12Certain Stock Options of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-J..
CI
01/12Certain Common Stock of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-JA..
CI
01/04Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
01/03Guggenheim Adjusts Price Target for Erasca to $20 From $25, Maintains Buy Rating
MT
2021ERASCA, INC.(NASDAQGS : ERAS) added to S&P Global BMI Index
CI
2021ERASCA, INC.(NASDAQGS : ERAS) added to NASDAQ Biotechnology Index
CI
2021Erasca Wins US FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme
MT
2021Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multifor..
GL
2021Erasca, Inc. Announces FDA Clearance of IND Application for Eras-801 in Glioblastoma Mu..
CI
2021Erasca to Be Included in Nasdaq Biotechnology Index
MT
2021Erasca Added to the Nasdaq Biotechnology Index
AQ
2021Erasca, Inc. Announces Change of Address
CI
2021Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference
AQ
2021Erasca Reports Third Quarter 2021 Financial Results and Business Updates - Form 8-K
PU
2021Earnings Flash (ERAS) ERASCA Reports Q3 Loss $-0.46
MT
2021Erasca Reports Third Quarter 2021 Financial Results and Business Updates
GL
2021ERASCA : Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhi..
AQ
2021Erasca, Inc. Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EG..
CI
2021ERASCA : is Named One of Fierce Biotech's “Fierce 15” Biotechnology Companies ..
AQ
2021ERASCA : Doses First Patient in Phase 1b/2 Trial of ERAS-007 in Gastrointestinal Cancer
MT
2021ERASCA : Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer..
AQ
2021Erasca, Inc. Announces First Patient Dosed in HERKULES-3, A Phase 1B/2 Gastrointestinal..
CI
2021ERASCA, INC.(NASDAQGS : ERAS) added to S&P TMI Index
CI
2021ERASCA : Doses First Patient in Lung Cancer Treatment Trial
MT
2021Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protoc..
GL
2021Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protoc..
CI
2021ERASCA : Pfizer Collaborate on Colorectal Cancer Combo Therapy
MT
2021Erasca in Clinical Trial Collaboration Agreement With Pfizer
DJ
2021PFIZER : Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to..
AQ
2021ERASCA : to Participate in the Morgan Stanley 19th Annual Global Healthcare Virtual Confer..
AQ
2021ERASCA : Reports Second Quarter 2021 Financial Results and Business Updates (Form 8-K)
PU
2021ERASCA : Q2 Loss Widens, Operating Expenses Rise
MT
2021Erasca Reports Second Quarter 2021 Financial Results and Business Updates
GL
2021ERASCA : Reports Second Quarter 2021 Financial Results and Business Updates
AQ
2021ERASCA : Earnings Flash (ERAS) ERASCA Posts Q2 Loss $-1.20
MT
2021Earnings Flash (ERAS) ERASCA Posts Q2 Loss $-1.20
MT
2021Erasca, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and..
CI
2021ERASCA : Evercore ISI Starts Erasca at Outperform With $45 Price Target
MT
2021ERASCA : Guggenheim Starts Erasca at Buy With $25 Price Target
MT
2021ERASCA : BofA Securities Starts Erasca at Buy With $28 Price Target
MT
2021ERASCA : JPMorgan Starts Erasca at Overweight With $28 Price Target
MT
2021ERASCA : Morgan Stanley Starts Erasca at Equal-Weight With $25 Price Target
MT
2021Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters' ..
GL
2021ERASCA : Opens Lower in Nasdaq Debut, Gains By Afternoon
MT
2021ERASCA : Prices IPO of 18.8 Million Common Shares at $16 per Share
MT
2021Erasca Announces Pricing of Upsized Initial Public Offering
GL
2021Erasca, Inc. has completed an IPO in the amount of $300 million.
CI
2021Erasca, Inc. has filed an IPO in the amount of $100 million.
CI
Upcoming event on ERASCA, INC.